Drugs / SONAVIBART
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04033406 | Aug 2019 → Nov 2021 | influenza | Vir Biotechnology, Inc. | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT05567783 | Oct 2022 → May 2023 | influenza | Vir Biotechnology, Inc. | Terminated | Missed primary |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2023-07-20 | Vir Biotechnology, Inc. | Results Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating VIR-2482 for the Prevention of Seasonal Influenza A Illness vir.bio ↗
In participants who received the highest dose of VIR-2482 (1,200 mg), a non-statistically significant reduction of approximately 16% in influenza A protocol-defined illness was observed. |
| 2020-10-21 | Vir Biotechnology, Inc. | Results Vir Biotechnology Presents New Data on VIR-2482, the Company’s Investigational Monoclonal Antibody for the Prevention of Influenza A, at IDWeek 2020 vir.bio ↗
Vir Biotechnology, Inc. (NASDAQ: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today announced the presentation of preclinical and Phase 1 data demonstrating the broad neutralizing ability, high-level effector function, extended half-life and tolerability of VIR-2482 in the prevention of influenza A. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-07-20 | Vir Biotechnology, Inc. | Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating VIR-2482 for the Prevention of Seasonal Influenza A Illness vir.bio ↗ |
| 2022-12-21 | Vir Biotechnology, Inc. | Vir Biotechnology Achieves Target Enrollment for Groundbreaking Phase 2 PENINSULA Trial Evaluating VIR-2482 for Prevention of Seasonal Influenza A vir.bio ↗ |
| 2022-10-18 | Vir Biotechnology, Inc. | Vir Biotechnology Announces First Patient Dosed in Groundbreaking Phase 2 Trial of VIR-2482 for Antibody Prophylaxis of Influenza A vir.bio ↗ |
| 2020-10-21 | Vir Biotechnology, Inc. | Vir Biotechnology Presents New Data on VIR-2482, the Company’s Investigational Monoclonal Antibody for the Prevention of Influenza A, at IDWeek 2020 vir.bio ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SONAVIBART | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068464 ↗ |
| Known as | VIR-2482 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05567783 ↗ |
| Modality | Monoclonal antibody | “VIR-2482, an engineered human monoclonal antibody with extended half-life, targets a highly conserved epitope on the stem region of influenza A hemagglutinin and may protect...” PMID 39036981 ↗ Oct 2024 |
| Route | Intramuscular | “VIR-2482 given by intramuscular injection” NCT04033406 ↗ |